Topokine Acquires Exclusive Rights to Revolutionary Technology for Manufacturing Topical Fat-Reducing Medications University of Bristol technology could improve manufacturing efficiency 5-10 fold; renowned scientist and inventor to join Company's Advisory Board
NEWTON, Mass., March 12, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics, a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, announced today that it has entered into an exclusive license agreement with the University of Bristol. Under the terms of the agreement, the Company has acquired exclusive worldwide rights to use, for all skin applications, a novel method to manufacture a class of prostaglandins that reduces fat. Additional terms were not disclosed.
The revolutionary technology, which one expert has called "unbeatable in its conciseness and elegance", greatly simplifies synthesis of prostaglandins. It is expected to improve manufacturing efficiency by 5-10 fold and substantially reduce manufacturing costs. The technology, featured in the September 13th, 2012 issue of Nature magazine, was developed at the University of Bristol by Professor Varinder Aggarwal and colleagues.
"There is remarkable synergy between our research and Topokine's innovative products. I look forward to helping advance Topokine's efforts by applying our synthesis technology," said Professor Aggarwal, a Fellow of the Royal Society who has joined Topokine's Advisory Board.
"Professor Aggarwal's group is at the cutting-edge of prostaglandin chemistry," said Murat Kalayoglu, MD, PhD, Topokine President & CEO. "This exclusive license further enhances our IP position, and we are excited to collaborate with him and the University of Bristol."
Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat. XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.
About the University of Bristol
The University of Bristol is consistently ranked among the leaders in UK higher education. Research-intensive and with an international reputation for quality and innovation, the University has over 18,000 students from over 100 countries, together with more than 5,000 staff. Places at Bristol are among the most highly sought after of all UK universities. The University was founded in 1876 and was granted its Royal Charter in 1909. It was the first university in England to admit women on the same basis as men. It is located in the heart of the city from which it grew, but is now a significant player on the world stage as well as a major force in the economic, social and cultural life of Bristol and South West England. Bristol is a member of the Worldwide Universities Network and of the Russell Group of leading research-intensive universities in the UK.
Media Contact: Murat Kalayoglu Topokine Therapeutics, Inc., email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Topokine Therapeutics, Inc.